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Abstract 
Background: Physical activity may be beneficial in Huntington’s disease, however studies 
to date have been underpowered to detect change. We combined data from five randomized 
controlled feasibility trials using individual patient data meta-analyses.  
Methods/Design: All trial interventions comprised a combination of supervised and self-
directed physical activity, with varied emphasis on aerobic, strength, endurance, flexibility, 
and task training. Duration ranged from eight to 16 weeks. The primary outcome was the 
modified Unified Huntington’s Disease Rating Motor Score. Secondary outcomes included 
the Symbol Digit Modality Test, Berg Balance Scale, 30-second Chair stand, Timed Up and 
Go, Gait speed, Physical Performance Test, six-minute Walk, International Physical Activity 
Questionnaire, Hospital Anxiety and Depression Scale, EuroQol Health Utility Index, Short-
Form 36 Health Related Quality of Life Scale. The primary analysis employed a two-stage 
approach. A one-stage approach was explored as a sensitivity analysis using a cross-classified 
(by study site) linear mixed effects model. 
Results. 121 participants provided complete data. Risk of bias was moderate; however 
primary outcomes were blind assessed.  Primary pooled effect estimates adjusted for baseline 
modified motor score (95% CI) were 0.2 (-.1 to 2.6) favoring control. There was 
considerable heterogeneity between the studies. 
Conclusions. There was no evidence of an exercise effect on the modified motor score in 
these relatively short duration interventions. Longer duration trials incorporating supervised 
components meeting frequency, intensity, time and type principles are required.  Lack of
common outcomes limited the analysis and highlight the importance of a core outcome set for 
evaluating exercise in Huntington’s disease.   
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Introduction. 
Huntington’s disease (HD) is a neurodegenerative disease which results in impairment of 
cognition, motor function, and behavior1. These impairments decrease independence in 
activities of daily living and quality of life2 even from relatively early in the disease.  At 
present, pharmacological interventions focus on symptom management, including decreasing 
chorea and minimizing depression and anxiety, however none have been effective in 
producing a disease-modifying effect. The evaluation of non-pharmacological interventions, 
such as exercise and physical activity, as both stand-alone and adjunctive therapies, has 
therefore never been more relevant.   
 
A recently published mixed methods systematic review3 suggests that there is preliminary 
support for the benefits of exercise and physical activity in HD in terms of motor function, 
gait speed, and fitness, as well as a range of physical and social benefits identified through 
patient-reported outcomes, however large sample randomized controlled trials are still 
unavailable.  Interventions that incorporated aerobic and strengthening programs in people 
with early-mid stage HD were recommended. This finding has been further supported by 
positive findings in a more recent study of high intensity exercise in people with HD4. There 
is equivocal evidence in support of multi-disciplinary rehabilitation interventions, which 
incorporate physical and occupational as well as a range of other functional training 
activities. While several studies5-11 report beneficial effects on a range of cognitive and motor 
outcomes, the strength of this evidence is relatively weak due to a lack of randomized 
controlled studies.   
 
Our group have conducted a series of randomized controlled trials (RCTs) focused on aerobic 
conditioning, strength training, flexibility and balance exercises, task-specific training and 
promotion of physical activity, and have demonstrated the feasibility, acceptability and safety 
of these interventions in people with early-mid stage HD12-16.  Although these studies have 
evaluated relatively short term (8-16 weeks) interventions, individually they have provided 
some indication that changes in motor function, mobility, endurance, fitness and quality of 
life can be achieved through regular exercise and physical activity.  
 
Large scale, long-term clinical trials, both pharmacological and non-pharmacological 
interventions, are limited in individuals with HD for several reasons, most notably because 
HD is rare and most clinics have wide geographical catchment areas. This latter i sue is 
further compounded in exercise trials, where in-person visits are essential to ensure 
intervention fidelity.  In order for exercise interventions in HD to progress, researchers must 
utilize statistical analysis, such as meta-analysis, that can combine datasets making the best
use of well-designed studies. 
 
Recently, with the advent of increased data sharing, meta-analyses utilizing the individual 
patient data (IPD) from each study have become more common.  A key advantage of IPD 
meta-analysis is that analyses across studies can be standardised and additional statistic
power may be available when baseline prognostic factors can be adjusted for consistently17.  
They are also more flexible when the effects of patient level treatment interactions are of 
interest18.  
 
The purpose of this paper is to present results from an individual patient data meta-analysis 
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conducted across five feasibility RCTs of exercise intervention in patients with HD12-16.  
 
Methods. 
Inclusion and exclusion criteria. All trials (n=5) included in this meta-analysis were 
small feasibility randomised controlled trials (RCTs) published by the same primary 
authors12-16. The trials examined supervised and self-directed exercise and physical activity 
interventions in patients with HD, used similar comparators and outcomes, and measured the 
isolated effects of exercise. Details of individual trial interventions, comparators, 
outcomes and analyses are shown in Table 1.  
 
Participants in the trials had to satisfy the following common inclusion criteria (1) diagnosis 
of HD, confirmed by genetic testing and eurological examination (2) over 18 years’ old and 
(3) on stable medication regimen for 4 weeks prior to initiation of trial and able to maintain a 
stable regime for the course of trial. Participants in ENGAGE-HD14, Move to Exercise15 and 
TRAIN-HD16 had difficulties with walking and/or balance whilst participants in COMMET-
HD12 had the ability to walk independently as a primary means of mobility. Participants in 
ExeRT-HD13 were able to use an exercise bike independently.  Common exclusion criteria 
were (1) any physical or psychiatric condition prohibiting the completion of the intervention 
or assessments, (2) or history of additional prior major neurological condition such as stroke 
or orthopaedic condition limiting mobility. 
 
Combined dataset. The data from each separate study were combined into one dataset for 
the individual patient data meta-analysis. Any outcomes that were recorded in two or more of 
the individual trials were included in the individual meta-analyses. Appropriate time-points 
were selected in the separate trials to consider as pre- and post- intervention time points in the 
meta-analysis. Repeat data from the same patient (identified by their unique ID) were 
removed from the primary dataset such that only the first occurrence in a trial for a 
participant was retained. 
 
Primary outcome. The Unified Huntington’s disease rating scale (UHDRS) modified 
motor score (mMS) was the primary outcome, calculated as the sum of scorings f r the items: 
dysarthria, tongue protrusion, finger taps left and right hand, pronate/supinate left and right 
hand, luria, gait, tandem walking and retropulsion pull. A higher score indicates a worse 
outcome.   
 
Secondary outcomes. Secondary outcomes included the Symbol Digit Modality Test 
(SDMT), Berg Balance Scale (BBS), 30-sec chair stand test (30sCST), imed Up and Go test 
(TUG), Gait speed (derived from 10-metre walk test), Physical Performance Test (PPT), Six-
minute walk test (6MWT), International Physical Activity Questionnaire (IPAQ), Hospital 
Anxiety and Depression Scale (HADS), EuroQol Health Utility Index (EQ5D), Short-Form 
36 Health Related Quality of Life Scale (SF-36).  The PPT scoring method was slightly 
different between trials; the original PPT was used in initial trials and the modified PPT in 
later trials). We used the available PPT component scores for all analyses. In ExeRT-HD, the 
2-minute walk was utilized as an outcome; we imputed 6MWT data from 2-minute walk dat .  
For all secondary outcomes except HADS and EQ5D a higher score denotes an improved 
outcome. 
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Risk of bias assessment. The risk of bias for each trial was assessed in accordance with the 
Cochrane Collaboration Guidelines19. Details of randomization; allocation concealment; 
blinding of intervention supervisors; blinding of participants; blinding of outcome assessors; 
handling of incomplete data; and reporting of results were considered.  
 
Power calculations, sample size and expected treatment effects. A retrospective power 
calculation was carried out in order to estimate the achieved power of the combined study as 
an aid only for interpretation and discussion rather than prospective design.  A final 
combined sample size of 121 patients was available for this individual patient data meta-
analysis. Based on a two-sided t-test, this provides 87% power at a 5% level of significance 
to detect a standardised effect size 0.4 equivalent to a decrease from a mean of 15 to 12.2 
(with a common SD of 7) for the primary outcome measure of the UHDRS modified motor 
score (mMS). 
 
Meta-analysis. Individual participant meta-analysis was carried out via a random effects 
linear regression two stage approach. A random effects model was used to account for st dy 
heterogeneity and allowed for a calculation of the contribution of each study to the overall 
treatment effect estimate. Heterogeneity was assessed using the I2 statistic as well as a visual 
inspection of the forest plot. 
 
Baseline values for outcomes were included where available as a covariate. Variables used to 
balance the randomization in all studies (age and gender) were also included in all models.  
Covariates considered for inclusion in the primary outcome model were: Total Functional 
Capacity (TFC) and Symbol Digit Modality Test (SDMT), where they were available in at 
least four of the studies. In two studies SDMT were derived from the UHDRS total cognitive 
scores. Analysis included participants who completed all assessments with available data. 
Only those outcomes where data were available for least 3 out of the 5 studies were included 
in the meta-analysis.  
 
Sensitivity analyses.  
Analyses of the primary outcome was also carried out via a one-stage individual participant 
data meta-analysis. Here a two-level mixed effects model was used to account for clustering 
within study. This also allowed for the addition of a cross-classified term to adjust for any 
additional possible correlation of four sites that were common to individual feasibility trials.  
Intra-cluster correlation coefficients (ICCs) were calculated from the cross-classified 
models20 and are presented as ICCsite (the ICC for participants in the same site but different 
studies), ICCstudy (the ICC for participants in the same study but different sites) and 
ICCcombined (the ICC for participants in the same site and study). A one stage sensitivity 
analysis including minimisation variables not present across all studies was also carried out. 
This resulted in some studies being excluded due to the complete case nature of the analysis.  
Numbers of participants included in each analysis are given in individual results tables.  
 
Subgroup analyses. Subgroup analyses of key baseline participant-level characteristics 
(age, gender, function at baseline (Total Functional Capacity (TFC)) and mMS at 
baseline. were performed on the primary outcome via the inclusion of 
subgroup*intervention interaction terms. Subgroup variables were cent red to ensure 
separation of within and across study interactions, within study interaction terms are 
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given in results18. The statistical analysis was conducted in Stata version v13.1 (StataCorp 
LP, USA). 
 
Ethical considerations including data ownership and confidentiality. 
Participants in the individual trials previously consented to their data being used for 
relevant research purposes.  Each trial has published its main results prior o th s meta-
analysis.  
 
 
Results. 
Study characteristics. Five studies were included in this individual patient data meta-
analysis3–7. Data for 158 participants were included in the combined dataset. Twelve 
participants took part in more than one trial and hence only the first occurrence was retained. 
Both age and gender were well balanced, as expected, since these variables were used in the 
minimization algorithms for all studies.  The average age of patients across all studies was 
53.2 years (SD 11.4) with little variation between studies. The proportion of males 
overall was 50.4% (61/121) with 48.4% in the control and 52.6% in the intervention 
across studies.  
 
Risk of Bias. Each study was carried out by the same lead investigators and followed 
similar protocols. Allocation concealment was achieved in each study via the 
implementation of a randomization process independent of recruitment to remove 
selection bias.  The study publications did not describe the process of sequence generation 
but personal communication with the study authors indicated that computer generated 
minimization algorithms were used in each study. Due to the nature of the intervention it was 
not possible to blind the participants and therapists, however in four out of five studies 
outcome assessors were blinded to minimize bias. In Move to Exercise, only the primary 
outcome assessment (UHDRS Total Motor Score (TMS), from which mMS is derive) 
and one further secondary outcome (BBS) were assessed blinded (using independent 
video rating). In common with most physiotherapy rehabilitation trials, each study was 
open so the risk of bias is therefore moderate. A key risk of bias assessment compares 
baseline outcomes measures in completers versus non-completers.  These data are given 
in Supplemental Table 1 and provide evidence that there is little drop-out bias present in 
the complete data set. 
 
Results of Published Studies. The original between-group intervention effects (95% 
confidence intervals) on mMS for four of five studies included (namely MtoE, 
COMMET-HD, EXERT-HD and ENGAGE-HD), were –4.5 [–8.8; –0.2] (n=21, favouring 
intervention); 2.4 [−0.9; 5.7] (n=21, favouring control); -2.87 [-5.42; -0.32] (n= 29), 
favouring intervention and 0.3 [-2.1; 3.40] (n=39, favouring control), respectively. Results 
for mMS were not reported in TRAIN-HD (only TMS was included as a motor 
outcome). 
 
Results of Individual Studies. Summary data for the primary outcome, the UHDRS 
modified motor score (mMS) for participants included in this individual patient data meta-
analysis are given in Table 2.  The total sample size of the complete data set is n=121.  
Participants who appeared in more than one trial (n=12) and participants who had missing 
 
 
8 
 
mMS score at either baseline or follow-up (n=25) were excluded. Overall the scores are 
slightly higher in the intervention arm than the control arm at baseline and remain higher in 
the intervention arm at follow-up.   
 
Results of Synthesis. Figure 1 shows the forest plot of the individual and combined study 
effects adjusted for mMS at baseline, age and gender.  There is considerable heterogeneity in 
the results of the five feasibility RCTs. Moreover the confidence intervals for each individual 
study are wide and cross the line of no effect. The main overall treatment effect is 0.23 (95% 
CI) (-2.10 to 2.56). The pooled effect demonstrated a small negative treatment effect for 
the intervention (higher mMS scores indicate worse motor impairment) that was not 
statistically significant (see Table 3). Additional covariates (TFC and SDMT) were included 
in the primary model. TFC was measured in all five studies but the sample size was reduced
slightly due to missing data, while the model with SDMT only included the four studies it 
was measured in. The inclusion of TFC, functional capacity at baseline, reversed the pooled 
effect to favour the intervention. SDMT itself was significantly predictive of outcome (higher 
baseline covariate levels were associated with improved outcome). However, including 
SDMT did not alter the main pooled treatment effect.  
 
Subgroup analysis. There were four pre-specified subgroup analyses for the primary 
outcome. The results of these analyses are shown in Supplemental Table 2.  None of the 
analyses suggested that there were any clinically relevant subgroup effects. 
 
Secondary outcomes. Only those secondary outcome present in at least 3 studies were 
included in the meta-analysis. (Table 4). None of outcomes demonstrated evidence of effect.  
Neither the ordinal or binary models for PPT converged and results are not presented.  This 
was most likely due to small numbers. 
 
Sensitivity analyses. Unadjusted effects and effects adjusted for baseline mMS and 
minimization variables (age and gender) are given for the cross-cla ified models in 
Supplemental Table 3. The treatment effect is slightly larger than the estimate obtained in 
the primary analysis with narrower confidence intervals.  This reflects the differing modeling 
estimation methods and assumptions of the two stage pooled and one stage mixed model but 
does not alter the conclusions.  The ICCs estimated from the mixed cross-classified models 
were mainly low but showed there was some variation in the outcome due to participants 
in the same study but different sites (ICCstudy) as well as participants from the same study 
and site (ICCcombined). These moderate ICCs reduced to close to zero when the model was 
adjusted for baseline mMS, suggesting that the clustering effect was mainly due to 
individual variation in baseline mMS. Leaving the cross-classification by site out of the one 
stage model gives an adjusted combined treatment effect and 95% CI of 0.4 (-0.9 to 1.6), the 
conclusions are therefore unchanged.  The second sensitivity analysis included those 
participants who took part in more than one of the studies included in this meta-analysis in a 
mixed repeated measures model. Twelve participants contributed additional results to this 
analysis however the estimates did not differ to the primary analysis (main effect and 95% CI 
0.04 (-0.8 to 1.6), p=0.473).   
 
Discussion. 
The majority of published exercise and physical activity trials and studies in HD to date have 
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been non-randomized interventions in small populations over relatively short durations with 
low study power. In five previous feasibility RCTs, we have shown that exercise 
interventions are feasible and acceptable in HD. Two of the studies also showed promising 
benefits in a range of physical and social patient reported outcomes. Here we have conducted 
the first ever individual patient data meta-analysis of randomized feasibility trials of exercise 
in people with HD where individual studies were not powered to test treatment effects.  
 
We did not find any clear evidence of an overall intervention effect on the primary motor 
outcome. Although adjusting for baseline functional capacity (TFC) reversed the pooled 
treatment effect in favour of the intervention there was no evidence of a differential effect for 
function in subgroup analyses suggesting variation between studies in baseline capacity. 
Although the study populations in these five trials were very similar with respect to age and 
gender, there was a large amount of heterogeneity in the primary outcome. This heterogeneity 
is likely from two sources, namely the interventions and the HD status of the included 
participants. The severity of HD as indicated by Disease Burden Score (DBS) was 
comparable in the two studies it was measured in, as was IPAQ and TFC therefore w  
surmise that variation in the patient populations can be discounted as the main source of 
heterogeneity.  
 
While all the interventions utilized some form of supervised and self-directed exercise and/or 
physical activity, the components, duration, intensity and frequency varied, hence t  
interventions and how participants responded varied considerably.  Moreover, some were 
conducted in a single or only two sites whilst others were larger multi-site trials. The 
intervention heterogeneity can be explained by the developmental stage of the evaluations 
that were included in this individual patient data meta-analyses. The UK Medical Research 
Council Framework for Development and Evaluation of Complex Interventions was 
followed. In this, an iterative process of feasibility and acceptability evaluations is conducted 
before moving to full scale efficacy evaluation. Detailed mixed methods evaluations were 
included in each of the five feasibility trials and each subsequent trial incorporated a slightly
different intervention focus based on the previous findings.  
 
The first trial, Move to Exercise, reported highly significant results. This is not unusual in 
small, single site studies, conducted by highly motivated investigators and where estimates 
can therefore be inflated. Whilst extremely encouraging, the importance of continuing to 
develop the evidence base for exercise in HD was recognized.  The subsequent trial, 
COMMET-HD, did not provide any signs of positive intervention effects. The process 
evaluation indicated that the intervention participants had not achieved a sufficiently intense 
exercise dose and had not engaged in self-directed exercise, although there was no indication 
why the control group had improved over and above the intervention group.  TRAIN-HD was 
a home-based physiotherapist delivered task-specific training intervention however did not 
incorporate any clear aerobic focus. In the TRAIN-HD process evaluation, whilst participants 
reported benefits these were not borne out in the study data. These findings led to the design 
of ExeRT-HD, a multi-center, highly supervised aerobic and task-specific training 
intervention conducted over a 12-week duration and ENGAGE-HD, a physical activity 
behavior change intervention which focused on encouraging individuals to set physical 
activity goals and engage in ongoing life-style physical activity.  The greatest positive effects 
of all trials in this study were noted in ExeRT-HD and Move to Exercise.  In ExeRT-HD the 
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intervention had been specifically designed based on knowledge gained from preceding 
feasibility trials to involve frequent and intensive supervised exercise. This was not quite 
enough to overcome the negative effects observed in COMMET-HD resulting in a pooled 
effect which did not favour the intervention. Heterogeneity in the primary results may 
indicate they are measuring different aspects of the intervention and pooled results should be 
interpreted with caution. 
 
Adequately powered large RCTs are difficult to achieve in rare conditions21, therefore 
alternatives are being sought.  Although randomised trials are the gold standard for obtaining 
unbiased treatment effect estimates, cohort non randomised interventional studies may be 
able to provide treatment effects that can be adjusted to account for the lack of randomistion.  
Methods used to adjust the estimates are the subject of current research by this group and 
others.  Statistical methods such as Propensity Score weighting allow researchers and 
analysts to provide approximations of treatment effects when randomised effects cannot be 
obtained.  
 
In our initial studies, and as part of the feasibility evaluations, we considered a range of 
outcomes, minimization variables and covariates. Some of these outcomes were not fasible
to collect and some were modified in subsequent trials. This meant that there was some 
missing data either at baseline or follow up for a range of the outcomes. One of the 
conclusions from this individual patient data meta-analysis is that a core outcome set for 
exercise interventions in HD patients would help standardize trial outcomes and aid further 
meta-analysis. If assessing outcomes of a short term intervention, it is critical that the primary 
outcome is selected based on the anticipated targets of that intervention that are along the 
causal pathway.  Although the UHDRS TMS (from which the modified motor score is 
derived) is the current gold standard for assessing motor impairment in HD, it is subject to 
rater bias and inherent variability particularly in the short term. A composite outcome may 
also better reflect the objectives of exercise studies in this population given that HD results in 
a triad of symptoms22.  
 
Our findings highlight the importance of including a measure of motor impairment as a 
baseline covariate in future trials. Furthermore, there should be consideration of disease 
severity (including cognition and apathy) in exercise prescription. In-depth exploration of 
relevant aspects of disease severity that limit exercise participation is urgently required to 
inform the development of interventions for later stage HD21. We conclude from the analyses 
reported here that future interventions must be delivered for longer durations and should 
consider frequency and intensity of exercise. Furthermore, supervision and support to 
exercise appear to be critical factors in facilitating adherence and optimizing outcome.     
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Table 1: Details of individual trial interventions, comparators, outcomes and analyses 
Trial Frequency and 
setting  
Exercise Mode  Comparator Outcomes Blinding and 
analyses 
Minimization variables 
(in addition to baseline 
scores) 
COMMET-
HD12 
(ISRCTN 
59910670); 
n=31 at 2 sites 
12 structured, 
gym-based, 
sessions plus 
home-based, 
independent 
2/week, 12 
weeks 
Aerobic 
training (cycle 
ergometer), 
functional 
strength 
training, 
regular walking 
programme 
Usual care UHDRS modified motor score 
UHDRS cognitive scales 
6-minute walk test (6mWT) 
10 metre walk test 
30-s chair stand test (30sCST) 
Romberg test 
Daily step counts 
% of sedentary time 
% time in moderate/ high physical activity  
Self-reported 7-day physical activity recall 
(IPAQ) 
SF-36 health related quality of life 
Submaximal exercise test (HR/ perceived 
exertion at minute 9) 
Assessor blind 
for all 
outcomes; 
complete case 
intention-to-
treat 
Gender, Disease Burden 
Score (DBS), physical 
activity 
ExeRT-HD13 
(ISRCTN1139
2629); n=32 at 
6 sites 
Structured 
exercises 
3/week (21/36 
supervised), 12 
weeks 
Aerobic 
training (cycle 
ergometer), 
functional 
strength 
training 
Usual care UHDRS modified motor score 
Symbol Digit Modality Test 
Word fluency 
Simple and complex dual task 
Trail making A & B 
Stroop 
3-minute walk test  
Finger tapping 
Self-reported 7-day physical activity recall 
(IPAQ) 
HADS 
EQ5D Health Index 
Weight (in kg) 
VO2 max 
Assessor blind 
for all 
outcomes; 
Complete case 
intention-to-
treat 
Age, UHDRS TMS, 
Gender; Site 
Move to 
Exercise 
(MtoE)15; 
n=21 at 1 site 
Home-based, 
DVD 
3/week; 8 
weeks 
Functional 
strength 
training, 
flexibility and 
balance 
Usual care UHDRS modified motor score 
Berg Balance Scale 
Gait analysis measures using Gait Rite 
including gait speed and spatiotemporal 
measures of gait  
SF-36 health related quality of life 
Assessor blind 
for 2 outcomes;  
(Berg Balance 
Scale; UHDRS 
modified  motor 
scale); 
Age, TFC 
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training (using 
exercise DVD) 
Complete case 
intention-to-
treat 
TRAIN-
HD16(ISCTR
N94284668); 
n=28 at 6 sites 
Supervised 
Home-based; 
twice/week; 8 
weeks 
Functional 
strength 
training, 
regular walking 
programme, 
task specific 
training 
Usual care UHDRS-Total Motor Score 
UHDRS cognitive scales 
Physical Performance Test 
Berg Balance Scale 
Gait Speed 
Fast Gait Speed 
30-s chair stand test (30sCST) 
Timed Up and Go test 
Goal Attainment Scale Vitality Score 
HADS 
HD QoL scale 
EQ5D Health Index 
Assessor blind 
for all 
outcomes; 
Complete case 
intention-to-
treat 
Gender, Site, DBS 
Engage-HD14 
(ISRCTN 
65378754); 
n=46 at 8 sites 
Supervised 1-
hour long 
home visits (6 
visits) home-
based, self-
directed;14 
weeks 
Regular 
walking 
programme, 
Functional 
strength 
training, 
flexibility and 
balance 
training (using 
exercise DVD) 
Social contact 
(inactive 
control) 
UHDRS modified motor score 
Symbol Digit Modality Test 
Category fluency 
Physical Performance Test  
6-minute walk test (6mWT) 
Timed Up and Go test 
Self-reported 7-day physical activity recall 
(IPAQ) 
Life Space Assessment 
Lorig Self-Efficacy Scale 
EQ5D Health Index 
ICE-CAP Health Utility Assessment 
Assessor blind 
for all outcomes 
Age, UHDRS TMS, 
Gender; Site 
 
  
 
 
19 
 
Table 2. Primary outcome summary data from each individual trial 
 Control 
 
Intervention 
 
 n Baseline 
Mean 
(SD) 
Follow-up 
Mean (SD) 
n Baseline 
Mean (SD) 
Follow-up 
Mean (SD) 
MtoE 7 18.7 (5.7) 21.1 (5.9) 8 19.1 (8.3) 17.5 (6.9) 
COMMET-HD 11 14.5 (7.9) 13.2 (7.0) 9 11.0 (6.4) 15.4 (5.1) 
TRAIN-HD 11 13.1 (6.8) 13.8 (5.6) 12 18.8 (6.5) 18.3 (6.0) 
ExeRT-HD 12 11.3 (5.4) 11.1 (5.3) 11 13.3 (6.1) 11.5 (6.4) 
ENGAGE-HD 23 14.6 (6.1) 14.1 (5.0) 17 14.5 (5.8) 14.7 (5.2) 
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Table 3. Primary outcome for IPD meta-analysis  
 
 n Treatment Effect 
(95% confidence 
interval) 
P-value 
mMS adjusted for baseline mMS, age 
and gender (primary model) 
121 0.2 (-2.1 to 2.6) 0.848 
mMS adjusted for baseline mMS, age, 
gender and TFC 
114 -0.7 (-2.0 to 0.7) 0.336 
mMS adjusted for baseline mMS, age,  
gender and SDMT 
104 0.3 (-1.8 to 2.5) 0.754 
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Table 4. Secondary outcomes for IPD meta-analysis  
Secondary outcomes adjusted for 
respective baseline scores, age 
and gender 
Number 
of studies 
n Treatment Effect 
95% confidence interval 
P-value 
Symbol Digit Modality Test 4 107 0.81 (-1.17 to 2.79) 0.422 
EQ5D 4 108 0 (-0.06 to 0.05) 0.900 
Timed Up and Go test 3 84 -1.64 (-3.59 to 0.31) 0.100 
6-minute walk test (6mWT) 3 85 18.77 (-6.02 to 43.56) 0.138 
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